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SH2 domains: modulators of nonreceptor tyrosine kinase activity
Panagis Filippakopoulos1, Susanne Mu¨ller1 and Stefan Knapp1,2The Src homology 2 (SH2) domain is a sequence-specific
phosphotyrosine-binding module present in many signaling
molecules. In cytoplasmic tyrosine kinases, the SH2 domain is
located N-terminally to the catalytic kinase domain (SH1) where
it mediates cellular localization, substrate recruitment, and
regulation of kinase activity. Initially, structural studies
established a role of the SH2 domain stabilizing the inactive
state of Src family members. However, biochemical
characterization showed that the presence of the SH2 domain
is frequently required for catalytic activity, suggesting a crucial
function stabilizing the active state of many nonreceptor
tyrosine kinases. Recently, the structure of the SH2–kinase
domain of Fes revealed that the SH2 domain stabilizes the
active kinase conformation by direct interactions with the
regulatory helix aC. Stabilizing interactions between the SH2
and the kinase domains have also been observed in the
structures of active Csk and Abl. Interestingly, mutations in the
SH2 domain found in human disease can be explained by SH2
domain destabilization or incorrect positioning of the SH2. Here
we summarize our understanding of mechanisms that lead to
tyrosine kinase activation by direct interactions mediated by
the SH2 domain and discuss how mutations in the SH2 domain
trigger kinase inactivation.
Addresses
1 Structural Genomics Consortium, University of Oxford, Old Road
Campus Research Building, Roosevelt Drive, Headington, Oxford OX3
7DQ, UK
2 Department of Clinical Pharmacology, University of Oxford, Old Road
Campus Research Building, Roosevelt Drive, Headington, Oxford OX3
7DQ, UK
Current Opinion in Structural Biology 2009, 19:643–649
This review comes from a themed issue on
Catalysis and Regulation
Edited by John Blanchard and Martin Noble
0959-440X# 2009 Elsevier Ltd.
DOI 10.1016/j.sbi.2009.10.001
Introduction
Protein kinase activity is tightly controlled in eukaryotic
cells. To guarantee quick and specific propagation of
cellular signals most kinases are locked in an inactive
state that can be rapidly activated by interaction with
regulatory elements such as interacting proteins or
domains located outside the catalytic domain as well as
post-translational modifications. In addition, selectivity of
signaling is dramatically enhanced by localizing kinases to
Open access under CC BY license.www.sciencedirect.comsignaling complexes and through selective targeting of
substrates via interactions with secondary substrate
recruitment sites.
SH2 domains represent the largest class of pTyr-selective
recognition domains in the human proteome [1,2]. In
cytoplasmic tyrosine kinases the arrangement of an
N-terminal SH2 domain followed by a kinase domain
is highly conserved in all family members and probably
evolved as an invariant signaling unit early in evolution
with the occurrence of tyrosine phosphorylation. The
conserved SH2–kinase domain unit has already been
reported to be present in the unicellular choanoflagellate
Monosiga brevicollis, a primitive common ancestor of mul-
ticellular organisms [3]. It is believed that this domain
arrangement initially served to target kinases to their
substrates [4]. With the increasing complexity of signaling
in multicellular organisms the flanking SH2 domain
assumed other regulatory functions such as allosteric
regulation of the kinase catalytic domain [5]. Interest-
ingly, already in M. brevicollis the Csk ortholog (MbCSK)
phosphorylates the Src ortholog MBSrc but the autoinhi-
bitory role of this phosphorylation event, which is a
hallmark of Src kinases inactivation, had not yet devel-
oped in Monosiga and evolved most likely much later
within the metazoan lineage [3].
The selectivity of SH2 domains for their pTyr substrates
has been investigated using directed phosphopeptide
library screening and a large number of biophysical and
biochemical studies [6–10]. These studies revealed that
most of the binding affinity (50%) is attributed to the
phosphate moiety of the pTyr residue while residues in
positions from 2 to +4, relative to the phosphotyrosine,
modulate binding specificity. However, structural studies
revealed larger contact interfaces spanning from residues
6 to +6 in some cocrystal structures [11,2].
In nonreceptor tyrosine kinases the conserved SH2–
kinase unit is flanked by a number of additional domains
which may comprise the N-terminal flanking region, a Src
homology 3 (SH3) domain, a second SH2 domain, a
sequence of PH–BTK–SH3 domains, a ‘Four-point-
one, Ezrin, Radixin, Moesin’ (FERM) domain, or an F-
BAR domain. In Abl kinases the C-terminus is extended
containing an F-actin binding domain (FABD) (Figure 1).
SH2 domain interactions leading to kinase
inactivation
The mechanism of autoinhibition of Src family members
has been elucidated by a number of high-resolution X-ray
crystallography studies [12,13,14]. The key event of SrcCurrent Opinion in Structural Biology 2009, 19:643–649
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Figure 1
Phylogenetic tree based on SH2 domain sequence and domain organization in nonreceptor tyrosine kinases. The different types of domain
architectures shown in the lower panel are highlighted by different colors and in the phylogenetic tree the name of kinases with a certain domain
organization are colored accordingly. The SH2–kinase unit is indicated by a dashed line. In Jak kinases this unit involves probably both kinase
domains, which seem to form a compact structural unit [34].inactivation is that the C-terminal Tyr527 in Src, or
a corresponding tyrosine in other family members, is
phosphorylated by Csk [15]. The phosphorylated
Tyr527 binds intramolecularly to the SH2 domain result-
ing in the formation of a compact inactive state. ThisCurrent Opinion in Structural Biology 2009, 19:643–649conformation is additionally stabilized by interactions of
the SH3 domain with proline rich sequences connecting
the SH2 domain and the kinase domain. Dephosphoryla-
tion of Tyr527 converts Src to an open active conformation
and triggers autophosphorylation of the activation segmentwww.sciencedirect.com
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lar dynamics simulation and mutational analysis showed
that the SH2 and SH3 domains of the inactive kinases are
tightly coupled by the connecting linker stabilizing the
inactive state in Src [16]. Interestingly also the isolated
SH3–SH2domains ofFynmaintain the relativeorientation
observed in the closed inactive kinase conformation of Src
[17]. In contrast the orientations of the SH2–SH3 domain
differed significantly in Lck which has a diverse linker
sequence suggesting that the linker between the SH2 and
SH3 domains affects the potential of the regulatory frag-
ments to repress kinase activity.
The crystal structure of the open active kinase confor-
mation of Src confirmed that the SH2/SH3 domain is
rotated away from the kinase domain but it retains its
‘clamp’ structure in which the SH3 domain remains
bound to the SH2 linker [18]. The open conformation
of the active Src kinase domain observed by crystallo-
graphy has been supported in solution by small-angle
scattering [19].
Many aspects of Src inactivation are conserved in Abl
kinases, which are also autoinhibited by intramolecular
interactions of the SH2/SH3 domains. However, autoinhi-
bition in Abl is phosphotyrosine independent [20,21]. The
lack of a residue corresponding to Src pTyr527 in Abl is
compensated for by an N-terminal myristoyl modification,
which tightly binds to the base of the kinase domain lower
lobe. This binding event induces bending of the C-term-
inal helix of the kinase domain and binding of the SH2 to
the kinase domain. Differences between the allosteric
regulation of Abl and Src result in distinct activation and
deactivation kinetics and pronounced selectivity of the
kinase inhibitor Gleevec for the Abl inactive state [22].
Zap70 and the closely related kinase Syk contain two N-
terminal SH2domains instead of theSrcSH3–SH2domain
arrangement (Figure 1). In the inactive state two helices of
the inter SH2 linker dock onto the C-terminal lobe helices
I and E [23]. The SH2–SH2 domain linker region con-
tains two tyrosine residues, which form aromatic stacking
interactions with the kinase domain. Phosphorylation of
these two residues activates Zap70 and allows binding of
immunoreceptor tyrosine-based activationmotifs (ITAM),
which arenot recognizedby the inactive complex.A similar
mechanism has been suggested for Syk [24]. Interestingly,
the SH2 domains in Zap70 have accessible pTyr binding
sites but high affinity binding to di-phosphorylated ITAM
is disrupted due to incompatible domain orientation that
disrupts the phosphotyrosine-binding pocket of the N-
terminal SH2 domain.
SH2 domain interactions stabilizing the kinase
active state
In the structure of active Src the SH2 domain does not
interact with the kinase domain and has no influence onwww.sciencedirect.comthe active state of this kinase. Indeed, deletion of the
entire N-terminal region comprising both the SH3 and
SH2 domains has little effect on Src kinase activity [25].
The situation is very different in Csk where the deletion
of the SH3 and SH2 domains results in a drastic reduction
of enzymatic activity [26–28]. Detailed mutagenesis
experiments showed that several residues in the SH2–
kinase linker region are important for catalytic activity
[27]. The crystal structure of full-length Csk revealed a
well-defined interaction site of the SH2 and SH3 domains
on either side of the N lobe and biochemical studies
demonstrate that these interactions stimulate the cataly-
tic activity of Csk [29].
SAXS analysis of active Brutons tyrosine kinase (Btk),
also revealed close proximity of the SH2 domain to the N
lobe of the kinase domain [30]. However, in contrast to
Csk the SH3–SH2–kinase domains assume an extended
conformation suggesting a well-defined and stable
arrangement of the domains distinct from the flexible
tethering observed in active c-Src. The presence of the
SH2 domain as well as the linker region between SH2 and
kinase domain has been shown to be necessary for activity
of Itk and, by analogy, also for the activity of other Tec
family members (Tec, Btk, Txk and Bmx). Site-directed
mutagenesis of residues in the conserved linker region of
Itk and Btk suggested a strong positive effect on kinase
activity [31,32]. Little is known about the function of the
SH2 domain in Jak kinases. Some members of that family
are lacking the invariant arginine residue that plays an
important role in coordinating phosphotyrosine ligands
[33]. It has been shown that Jak function is independent
of phosphotyrosine binding and it is assumed that the Jak
SH2 domain plays a structural role rather than serving as a
substrate recruitment module and its influence on Jak
kinase activity is unknown [34].
Also the active state of Abl is stabilized by a tight contact
of the SH2 domain with the upper kinase lobe [35].
Mutation of residues located in the interface significantly
impaired Abl catalytic activity and the SH2–kinase unit of
Abl is about fourfold more active than the isolated kinase
domain [35,36]. The interaction of the SH2 domain
with the upper lobe of the kinase domain has been
supported by deuterium exchange studies using mass
spectroscopy [37]. The precise mechanism by which
the SH2 domain activates kinase function by this inter-
action remains enigmatic.
In Fes/Fps insertion mutagenesis identified the SH2
domain as a strongly positive regulator of kinase activity.
Dipeptide insertions in the N-terminal region of the v-
Fps SH2 domain cause a severe loss of both kinase and
transforming functions, suggesting that the conformation
of the SH2 domain is important for the catalytic proper-
ties of the adjacent kinase domain [38,39]. The stableCurrent Opinion in Structural Biology 2009, 19:643–649
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Figure 2
Interfaces between kinase domains and SH2/linker. (a) SH2–kinase domain arrangement in Fes. Shown is the orientation of the domains in low-
resolution surface representation in the left panel. Structural details upon inactivation are shown in the middle panel and a detailed view of the SH2–aC
interaction is shown in the right panel. Key residues of the interaction are highlighted. (b) Domain organization in active Csk. (c) Domain organization in
inactive Zap70. (d) Domain packing in inactive Abl (left panel), active Abl (middle panel), and detailed view of the interaction between the SH2 domain
and the kinase domain (right panel). As indicated in the lower panel in all surface representations SH3 domains are shown in orange, SH2 domains in
blue, linker regions between SH2 and kinase domain in yellow, helix aC in red, activation segments in purple and the kinase domains are shown in
beige.character of the SH2–kinase unit was further demon-
strated by limited trypsin digestion, which yielded a
protease-resistant 45 kDa fragment containing both the
SH2 and kinase domains [40]. The crystal structure of
active Fes revealed a compact structural unit of the SH2–
kinase domain in which the catalytically important helix
C is positioned in tight contact with the SH2 domain
[36]. In contrast to Src family members the SH2 domain
moves away from the kinase domain in inactive Fes. The
separation of the SH2 and kinase domains and absence of
a ligand occupying the SH2 binding site result in partialCurrent Opinion in Structural Biology 2009, 19:643–649unfolding of the SH2 domain and higher mobility of aC in
the kinase domain. Thus, binding of a primed substrate to
the Fes SH2 domain is an early step in Fes activation that
results in allosteric regulation of the catalytic domain.
The different scenarios of kinase activation and inacti-
vation by SH2 domains are summarized in Figure 2.
Role of destabilizing mutations in the SH2
domain and linker region in disease
The SH2 domain is a key regulator of allosteric kinase
regulation and may play a role in both the inactive as wellwww.sciencedirect.com
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Figure 3
Location of mutations identified in human disease projected onto the
structure of the Btk SH2 domain. Data used in the figure were taken from
Ref. [45]. Mutations that destabilize the SH2 domain are shown in
yellow and those affecting pTyr binding are highlighted in blue. The
locations of the destabilizing mutation R335W in Itk, P80Q in Zap70, and
W460C in Fer are also shown. The major structural elements harboring
mutations as well as the C-termini and N-termini are labeled.as the active states of tyrosine kinases. It is therefore no
surprise that mutations have been identified in patients
that compromise SH2 function and as a consequence
kinase activity. A recent survey found that the majority
of the disease-causing missense mutations in SH2
domains affect functionally important amino acids
(71%) either directly involved in ligand binding, or resi-
dues that mediate interactions with the catalytic domain.
The remaining missense mutations are located distantly
from the SH2 domain and presumably affect its stability
[41]. In Fes, the structure of the SH2–kinase unit
revealed a mechanism that explains how destabilization
of the SH2 domain can affect enzymatic activity by
relocating the SH2 domain and effectively losing contact
with the kinase domain. In the closely related kinase Fer
a mutation of the highly conserved residue (W460C)
located in the N-terminus of the SH2 domain has been
detected in lung cancer [42]. Trp460 is part of the
hydrophobic core of the SH2 domain and is not involved
in pTyr binding. This residue is also conserved in Fes and
its location suggests that it is an essential residue for SH2
domain stability resulting in kinase inactivation and most
likely rapid degradation of the protein in the cellular
environment. Similarly, the missense mutation P80Q in
Zap70 causes severe combined immunodeficiency
(SCID) by reducing the stability of the Zap70 SH2
domain associated with rapid degradation of the protein
[43]. A destabilizing mutation (E481G) causing SCID has
also been reported for the Jak3 SH2 domain [44].
One of the best studied examples of disease-causing
mutations in SH2 domains is the Tec family member
Btk. Mutations in the SH2 domain of this kinase cause X-
linked agammaglobulinemia (XLA), a prototypical
humoral immunodeficiency characterized by low levels
of circulating B cells and a drastic reduction in serum
concentrations of immunoglobulins [45]. So far more
than 30 missense mutations in the BTK SH2 domain
have been described in XLA patients and the effects of
these mutations have been analyzed by a large number of
in vitro and in vivo studies [45,46–48]. About 20
mutations are directly involved in ligand binding and
disturb the interaction with signaling partners, like
SLAM family members and SH2D1A. The remaining
mutations are located outside the ligand-binding pocket
and affect protein stability, resulting in reduced half-life
of the mutated protein in cells. Recently a mutation in the
SH2 domain of the Tec family member Itk has been
linked to severe immune dysfunction and therapy-resist-
ant Epstein–Barr virus (EBV)-positive B cell prolifer-
ation. The mutation R335W is located in the BG loop
of the Itk SH2 domain. Arg335 is not involved in pTyr
binding and mutation to tryptophan most likely causes
instability of the SH2 domain and significantly reduced
protein levels in patients as a result of increased protein
degradation [49]. Since a functional SH2 domain is
necessary for enzymatic activity it is likely that also kinasewww.sciencedirect.comactivity is compromised in mutants that destabilize the
SH2 domain in Tec family members [31,32]. A summary
of mutants identified in human disease and their location
is shown in Figure 3.
Structural data and mutations found in human disease
that lead to SH2 domain destabilization suggest a pivotal
role of the SH2 domain in structural stability and in the
stabilization of the active kinase conformation for a large
number of nonreceptor tyrosine kinases. We hope that
further structural and functional studies on multidomain
constructs of tyrosine kinases will shed further light on
the diverse mechanisms of kinase activation for this
important group of enzymes.
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